Sanofi v Amgen dispute: Australian update
It’s one of the most consequential pharmaceutical patent disputes in years, one that is being closely watched by practitioners around the world. The patent litigation concerning Amgen’s PCSK9 antibody...
It’s one of the most consequential pharmaceutical patent disputes in years, one that is being closely watched by practitioners...
Read More
No pay day for Commonwealth in Sanofi pharmaceutical damages claim
Background In the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal Court of Australia has upheld the trial judge’s decision that...
Background In the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal...
Read More
Full Court finds that usual undertaking for damages is not limited by TG Act
The fact that the Therapeutic Goods Act 1989 contains provisions that permit the Commonwealth, among other parties, to recover compensation in certain pharmaceutical patent infringement proceedings does not preclude...
The fact that the Therapeutic Goods Act 1989 contains provisions that permit the Commonwealth, among other parties, to recover...
Read More
Landmark Judgement: Methods of Medical Treatment are Patentable
In a landmark decision1 the High Court of Australia has affirmed that methods of medical treatment of humans constitute patentable subject matter and, more specifically, that methods of medical...
In a landmark decision1 the High Court of Australia has affirmed that methods of medical treatment of humans constitute...
Read More
Sanofi v Eremad Pty Ltd [2013] ATMO 94
This matter concerned an opposition to registration of the mark CLOVIX 75 in respect of class 5 Pharmaceutical preparations being products containing clopidogrel. The mark was opposed by French...
This matter concerned an opposition to registration of the mark CLOVIX 75 in respect of class 5 Pharmaceutical preparations...
Read More